KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2025)

Sarepta Therapeutics has reported Gross Margin over the past 9 years, most recently at 9.98% for Q4 2025.

  • Quarterly results put Gross Margin at 9.98% for Q4 2025, down 6992.0% from a year ago — trailing twelve months through Dec 2025 was 61.81% (down 2142.0% YoY), and the annual figure for FY2025 was 61.81%, down 2142.0%.
  • Gross Margin for Q4 2025 was 9.98% at Sarepta Therapeutics, down from 62.25% in the prior quarter.
  • Over the last five years, Gross Margin for SRPT hit a ceiling of 96.04% in Q4 2022 and a floor of 77.6% in Q3 2022.
  • Median Gross Margin over the past 5 years was 82.89% (2021), compared with a mean of 50.72%.
  • Biggest five-year swings in Gross Margin: tumbled -16523bps in 2022 and later surged 16563bps in 2023.
  • Sarepta Therapeutics' Gross Margin stood at 84.24% in 2021, then rose by 14bps to 96.04% in 2022, then dropped by 0bps to 95.9% in 2023, then dropped by -17bps to 79.91% in 2024, then tumbled by -88bps to 9.98% in 2025.
  • The last three reported values for Gross Margin were 9.98% (Q4 2025), 62.25% (Q3 2025), and 75.04% (Q2 2025) per Business Quant data.